BC
CELG

Bartlett & Co’s Celgene Corp CELG Stock Holding History

Bartlett & Co’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$53K Buy
535
+315
+143% +$29.9K ﹤0.01% 522
2019
Q2 		$20K Hold
220
– – ﹤0.01% 533
2019
Q1 		$21K Sell
220
-90
-29% -$7.87K ﹤0.01% 518
2018
Q4 		$20K Sell
310
-100
-24% -$7.38K ﹤0.01% 521
2018
Q3 		$37K Hold
410
– – ﹤0.01% 472
2018
Q2 		$33K Sell
410
-900
-69% -$74.7K ﹤0.01% 473
2018
Q1 		$117K Sell
1,310
-850
-39% -$81.6K ﹤0.01% 305
2017
Q4 		$225K Buy
2,160
+100
+5% +$11.3K 0.01% 246
2017
Q3 		$300K Hold
2,060
– – 0.01% 221
2017
Q2 		$268K Sell
2,060
-50
-2% -$6.13K 0.01% 231
2017
Q1 		$263K Buy
2,110
+810
+62% +$96.9K 0.01% 228
2016
Q4 		$150K Buy
+1,300
New +$145K 0.01% 272
2016
Q3 		– Sell
-25
Closed -$2K – 757
2016
Q2 		$2K Buy
+25
New +$2.59K ﹤0.01% 702
2015
Q1 		– Sell
-125
Closed -$14K – 849
2014
Q4 		$14K Buy
+125
New +$13.2K ﹤0.01% 587

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bartlett & Co's CELG Position: Q3 2019 in Review

Bartlett & Co increased its Celgene Corp (CELG) stake by 143% in Q3 2019, buying an estimated $29.9K and bringing the position to 535 shares worth $53K. The position accounts for ﹤0.01% of the portfolio, ranked #522.

Bartlett & Co first reported a position in CELG in Q4 2014 and has held it in 14 quarters since. The position peaked at $300K in Q3 2017. 1,245 funds tracked by Wall St. Rank hold CELG as of Q3 2019.

  • Bartlett & Co held 535 shares of Celgene Corp worth $53K as of Q3 2019.
  • Bartlett & Co bought 315 Celgene Corp shares in Q3 2019, an estimated $29.9K.
  • Celgene Corp made up ﹤0.01% of Bartlett & Co's portfolio in Q3 2019, its #522 holding.
  • Bartlett & Co first reported a position in Celgene Corp in Q4 2014 and has held it in 14 quarters since.
  • Bartlett & Co's Celgene Corp position peaked at $300K in Q3 2017.
  • 1,245 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2019.

Based on Bartlett & Co's 13F filing for Q3 2019, filed 4 Nov 2019.